GlassScriptPhysician profile
Ashley P Perel
NPI 1891575056
$1,282.38
in general payments reported to CMS, 2019-2025
17 companies · $717 in 2025
The $717 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $30.72 · 2024: $535 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $227.27 | 2024-2025 | Verquvo, Lynparza, Keytruda |
| Fennec Pharmaceuticals, INC. | $202.48 | 2025 | Fyarro |
| Scpharmaceuticals INC. | $169.62 | 2025 | |
| Pfizer INC. | $124.60 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $104.24 | 2023-2025 | |
| Smith+Nephew, INC. | $98.25 | 2024 | Stravix, Grafix Pl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.40 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $58.45 | 2024 | Lynparza, Wainua, Farxiga |
| Cvrx, INC. | $49.69 | 2024-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $37.77 | 2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $24.95 | 2024 | Arcalyst |
| Boston Scientific Corporation | $23.96 | 2025 | Watchman Access System |
| Esperion Therapeutics, INC. | $23.72 | 2024 | Nexletol |
| Recor Medical INC | $23.35 | 2024 | Paradise Renal Denervation System |
| Novo Nordisk INC | $19.71 | 2024 | Wegovy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18.89 | 2024 | Zejula, Jemperli |
| Janssen Pharmaceuticals, INC | $15.03 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Perel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.